Purple Biotech Partners with Converge Bio for AI Oncology Acceleration
Ticker: PPBT · Form: 6-K · Filed: Mar 25, 2026 · CIK: 0001614744
Complexity: simple
Sentiment: bullish
Topics: collaboration, biotech, AI, oncology
TL;DR
**Purple Biotech just teamed up with Converge Bio to use AI for faster cancer drug development!**
AI Summary
Purple Biotech Ltd. announced on March 25, 2026, a new AI collaboration with Converge Bio aimed at accelerating the development of their oncology pipeline. This partnership is significant because it leverages artificial intelligence to potentially speed up drug discovery and development, which could lead to new treatments for cancer and increase the company's value for investors by bringing products to market faster.
Why It Matters
This collaboration could significantly reduce the time and cost of drug development, potentially bringing new cancer treatments to market faster and increasing Purple Biotech's revenue potential.
Risk Assessment
Risk Level: medium — While AI collaboration offers potential benefits, the success of drug development remains inherently risky and long-term, with no guaranteed outcomes.
Analyst Insight
A smart investor would monitor future announcements regarding the progress of this AI collaboration, as successful integration and results could significantly boost Purple Biotech's long-term value.
Key Players & Entities
- Purple Biotech Ltd. (company) — the filer announcing the AI collaboration
- Converge Bio (company) — the partner in the AI collaboration
- March 25, 2026 (date) — the filing and report period date
Forward-Looking Statements
- Purple Biotech will announce specific milestones or early successes from the AI collaboration within the next 12-18 months. (Purple Biotech Ltd.) — medium confidence, target: 2027-09-25
FAQ
What is the primary purpose of the collaboration between Purple Biotech and Converge Bio?
The primary purpose of the collaboration is to accelerate the development of Purple Biotech's oncology pipeline by leveraging artificial intelligence, as stated in the EX-99.1 document titled 'PURPLE BIOTECH ANNOUNCES AI COLLABORATION WITH CONVERGE BIO TO ACCELERATE DEVELO'.
When was this 6-K filing submitted and accepted by the SEC?
The 6-K filing was submitted and accepted by the SEC on March 25, 2026, according to the filing detail information.
What type of business does Purple Biotech Ltd. primarily engage in, according to its SIC code?
Purple Biotech Ltd. primarily engages in 'Pharmaceutical Preparations', as indicated by its SIC code 2834.
Where is Purple Biotech Ltd.'s business address located?
Purple Biotech Ltd.'s business address is 4 Oppenheimer Street, Science Park, Rehovot L3, 7670104, as listed in the filing.
What is the CIK number for Purple Biotech Ltd.?
The CIK number for Purple Biotech Ltd. is 0001614744, as provided in the filing details.
Filing Stats: 502 words · 2 min read · ~2 pages · Grade level 20 · Accepted 2026-03-25 08:05:24
Filing Documents
- ea0283345-6k_purple.htm (6-K) — 14KB
- ea028334501ex99-1.htm (EX-99.1) — 21KB
- ea028334501_ex99-1img1.jpg (GRAPHIC) — 8KB
- 0001213900-26-033843.txt ( ) — 47KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. March 25, 2026 PURPLE BIOTECH LTD. By: /s/ Gil Efron Gil Efron Chief Executive Officer 2